A 9-year run for VLST has ended. The Seattle biotech outfit has peddled assets to undisclosed buyers for undisclosed terms and shut its doors for good, Xconomy 's Luke Timmerman reported.
Apexigen, a Burlingame, CA-based company that was spun out of Epitomics three years ago, says that much of the money will be used to work on an in-house cancer immunotherapy dubbed APX005.
New backers have upped Cleveland-based BioMotiv's financial backing to $46 million, substantially increasing the firepower of an early-stage drug developer looking to assemble a portfolio of new therapies under its wing.
Karyopharm has scored an additional $19 million for its Series B round of financing, padding the $48.2 million raised for the round in May, for a total of more than $67 million, among the largest this year for a drug developer.
Alongside the traditional venture investors who came back for this round, Dicerna also attracted a group of public company investors lured by the prospects of a biotech company keeping a close watch on the current groundswell of IPOs popping up in the industry.
Germantown, MD-based Intrexon, a synthetic biology outfit led by billionaire Randal Kirk, aims to sell 8.3 million shares at a proposed range of $14 to $16 per share.
Edimer aims to use the new funds to bankroll a midstage study of its lead candidate EDI200, a recombinant protein intended to restore normal development in newborns with XLHED.
Foundation Medicine has bought a ticket to ride the IPO train. The Cambridge, MA-based company, which provides genomic tests for cancer patients and drug researchers, has proposed an $86.3 million initial public offering.
Five Prime Therapeutics wants to follow more than two dozen other drug developers this year onto the public market. The South San Francisco-based biotech, a developer of protein drugs, has filed paperwork to complete an initial public offering.
aTyr Pharma has raised $49 million in a Series D financing that included money from "one of the largest public funds in the world," Executive Chairman and CEO John Mendlein said.